新京报贝壳财经讯（记者黄鑫宇）12月26日晚，北交所官网显示，安徽济人药业股份有限公司（即"济 人药业"，874919）IPO申请获北交所受理。 2023年3月，济人药业曾向上交所主板提交IPO申报，但2025年2月主动撤回。随后济人药业便启动了北 交所上市辅导、申报新三板挂牌等相关工作。不到一年，济人药业IPO申请被北交所受理。 2023年、2024年，济人药业实现营业收入分别约为11.34亿元、12.30亿元，实现归母净利润分别约为 1.31亿元、1.32亿元。 本次IPO，济人药业选择的是北交所第一套上市标准，即预计市值不低于2亿元，最近两年净利润均不 低于1500万元且加权平均净资产收益率平均不低于8%，或者最近一年净利润不低于2500万元且加权平 均净资产收益率不低于8%。 济人药业拟募资金额约为5.26亿元，主要用于"年产450吨中药配方颗粒项目""年产8000吨中药饮片项 目""研发中心建设项目""营销网络建设项目"及"补充流动资金"。 济人药业是一家中药药企，主要产品包括中成药、中药饮片、中药配方颗粒三大类。已被录入甲型 H1N1流感、人感染H7N9禽流感、新冠病毒感染等疾病中成药诊疗方案的疏 ...

Core Viewpoint - Jiren Pharmaceutical is advancing its IPO process after transitioning from the Shanghai Stock Exchange to the Beijing Stock Exchange, with a focus on its core product, Shufeng Jiedu Capsule, which is included in treatment plans for various viral infections [1][2]. Company Overview - Jiren Pharmaceutical, established in April 2001, has developed into a modern Chinese medicine manufacturer integrating standardized planting of medicinal materials, production, and sales of traditional Chinese medicine [6]. - The company has ventured into the financial sector by holding a 0.18% stake in Bozhou Yaodu Rural Commercial Bank since 2018 [6]. Product Information - Shufeng Jiedu Capsule is a proprietary product of Jiren Pharmaceutical, primarily used for treating upper respiratory infections and various viral diseases [2]. - The market share of Shufeng Jiedu Capsule is currently 4.24%, ranking third among cold medicine brands, following Yiling Pharmaceutical's Lianhua Qingwen Granules and Haitai Pharmaceutical's Sijikang Antiviral Mixture [3][2]. Financial Performance - Jiren Pharmaceutical reported revenues of approximately CNY 1.134 billion and CNY 1.230 billion for 2023 and 2024, respectively, with net profits of CNY 131 million and CNY 132 million [6]. - Sales revenue for Shufeng Jiedu Capsule is projected to decline, with expected revenues of CNY 475 million in 2023 and CNY 377 million in 2024 [3][4]. Regulatory Scrutiny - The National Equities Exchange and Quotations (NEEQ) has raised concerns regarding the high academic promotion costs for Shufeng Jiedu Capsule despite its long-standing inclusion in medical insurance, as well as the effectiveness of measures to isolate commercial bribery risks between the company and its promoters [1][5]. - Jiren Pharmaceutical has engaged 299 and 273 promoters for academic promotion in 2023 and 2024, respectively, and has conducted visits to over 590,000 and 536,000 individuals in relevant medical departments [5].